WO2004011024A8 - Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel - Google Patents

Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel

Info

Publication number
WO2004011024A8
WO2004011024A8 PCT/AT2003/000208 AT0300208W WO2004011024A8 WO 2004011024 A8 WO2004011024 A8 WO 2004011024A8 AT 0300208 W AT0300208 W AT 0300208W WO 2004011024 A8 WO2004011024 A8 WO 2004011024A8
Authority
WO
WIPO (PCT)
Prior art keywords
thrombin
active ingredient
pharmaceutical active
generating capacity
medicaments
Prior art date
Application number
PCT/AT2003/000208
Other languages
English (en)
French (fr)
Other versions
WO2004011024A1 (de
Inventor
Johann Eibl
Original Assignee
Bio Prod & Bio Eng Ag
Johann Eibl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Prod & Bio Eng Ag, Johann Eibl filed Critical Bio Prod & Bio Eng Ag
Priority to YUP-2005/0051A priority Critical patent/RS20050051A/sr
Priority to EP03770985A priority patent/EP1523327A1/de
Priority to AU2003246449A priority patent/AU2003246449A1/en
Publication of WO2004011024A1 publication Critical patent/WO2004011024A1/de
Priority to US11/041,165 priority patent/US7494971B2/en
Publication of WO2004011024A8 publication Critical patent/WO2004011024A8/de
Priority to US12/355,507 priority patent/US20090123453A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Abstract

Die Erfindung betrifft eine pharmazeutische Wirkstoffzubereitung zur Herstellung eines thrombingenerierfähigen oder thrombinhältigen Arzneimittels und ist dadurch gekennzeichnet, dass sie enthält: (A) aus Plasma oder gentechnologisch gewonnenes Prothrombin (Gerinnungsfaktor II), (B) aus Plasma oder gentechnologisch gewonnene Gerinnungsfaktoren V, VIII, IX, X, die zumindest teilweise in aktiviertem Zustand vorliegen können, und aus Plasma oder gentechnologisch gewonnenen Gerinnungsfaktor Xla, und (C) prionensichere, gerinnungsaktive Phospholipide, wobei die Phospholipide gegebenenfalls in Liposomen enthalten sind.
PCT/AT2003/000208 2002-07-23 2003-07-23 Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel WO2004011024A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
YUP-2005/0051A RS20050051A (en) 2002-07-23 2003-07-23 Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity
EP03770985A EP1523327A1 (de) 2002-07-23 2003-07-23 Thrombingenerierfahige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
AU2003246449A AU2003246449A1 (en) 2002-07-23 2003-07-23 Pharmaceutical active ingredient preparations and medicaments that contain thrombin or have a thrombin-generating capacity
US11/041,165 US7494971B2 (en) 2002-07-23 2005-01-21 Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin
US12/355,507 US20090123453A1 (en) 2002-07-23 2009-01-16 Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT11132002 2002-07-23
ATA1113/2002 2002-07-23
PCT/AT2003/000204 WO2004011023A1 (de) 2002-07-23 2003-07-21 Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
ATPCT/AT03/00204 2003-07-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/041,165 Continuation US7494971B2 (en) 2002-07-23 2005-01-21 Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin

Publications (2)

Publication Number Publication Date
WO2004011024A1 WO2004011024A1 (de) 2004-02-05
WO2004011024A8 true WO2004011024A8 (de) 2007-05-18

Family

ID=30773865

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/AT2003/000204 WO2004011023A1 (de) 2002-07-23 2003-07-21 Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
PCT/AT2003/000208 WO2004011024A1 (de) 2002-07-23 2003-07-23 Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/AT2003/000204 WO2004011023A1 (de) 2002-07-23 2003-07-21 Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel

Country Status (9)

Country Link
US (2) US7371722B2 (de)
EP (2) EP2082748A1 (de)
AT (1) ATE428440T1 (de)
AU (2) AU2003246448A1 (de)
DE (1) DE50311422D1 (de)
DK (1) DK1528930T3 (de)
ES (1) ES2325956T3 (de)
RS (1) RS52080B (de)
WO (2) WO2004011023A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
ES2926359T3 (es) 2003-12-01 2022-10-25 Novo Nordisk Healthcare Ag Filtración de virus de composiciones líquidas del Factor VII
WO2007095175A2 (en) * 2006-02-15 2007-08-23 Massachusetts Institute Of Technology Thermo-responsive materials
EP2305289A1 (de) * 2009-09-16 2011-04-06 Bio-Products & Bio-Engineering Aktiengesellschaft Medizinische Produkte zur Behandlung von Blutgerinnungsstörungen
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
CA2823005C (en) 2010-12-30 2019-07-09 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
IL230150A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
CN112011527B (zh) * 2020-08-25 2023-07-07 长春雷允上药业有限公司 一种凝血酶的制备方法
AU2021348528A1 (en) 2020-09-23 2023-06-08 Omrix Biopharmaceuticals Ltd. Hemostatic formulations and uses thereof
CN113018423A (zh) * 2021-03-12 2021-06-25 上海利康瑞生物工程有限公司 一种基于乙醇梯度洗脱的止血材料及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
US4286056A (en) * 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
EP0044343B1 (de) * 1980-01-28 1984-08-22 Baxter Travenol Laboratories, Inc. Prothrombin enthaltende therapeutische zusammensetzungen und verfahren zur herstellung enzymatisch aktiver blutgerinnungsfaktoren aus prothrombin enthaltenden blutfraktionen
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
CA2285935C (en) * 1997-04-08 2011-01-18 Baxter Aktiengesellschaft An immunotolerant prothrombin complex preparation
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
DE19824306A1 (de) * 1998-05-21 1999-11-25 Michael Sittinger Autologe Fibrinkleber
RS20050051A (en) * 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity

Also Published As

Publication number Publication date
ATE428440T1 (de) 2009-05-15
AU2003246449A1 (en) 2004-02-16
RS52080B (sr) 2012-06-30
AU2003246448A1 (en) 2004-02-16
US20050192222A1 (en) 2005-09-01
WO2004011024A1 (de) 2004-02-05
EP1528930A1 (de) 2005-05-11
AU2003246449A8 (en) 2004-02-16
US7371722B2 (en) 2008-05-13
EP1528930B1 (de) 2009-04-15
EP2082748A1 (de) 2009-07-29
ES2325956T3 (es) 2009-09-25
RS20050052A (en) 2007-06-04
DE50311422D1 (de) 2009-05-28
US20090123453A1 (en) 2009-05-14
WO2004011023A1 (de) 2004-02-05
DK1528930T3 (da) 2009-08-03

Similar Documents

Publication Publication Date Title
Sitko et al. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
WO2004011024A8 (de) Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
Hedner Recombinant activated factor VII: 30 years of research and innovation
HK1099511A1 (en) Method for the production of an administration form which is secured against misuse
WO2003082247A3 (en) Drug microparticles
WO2005099709A3 (en) Bicyclic heterocycles useful as serine protease inhibitors
WO2004043363A3 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004094372A3 (en) Compounds useful as serine protease inhibitors
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
WO2001070968A3 (en) Production of recombinant blood clotting factors in human cell lines
WO2004080971A8 (en) Tetrahydroquinoline derivatives useful as serine protease inhibitors
WO2004054607A3 (de) Stabile therapeutische proteine
WO2001077113A3 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
WO2007011390A3 (en) Large-scale production of human serum butyrylcholinesterase as a bioscavenger
JP2007513190A5 (de)
WO2008063717A3 (en) Pharmaceutical manufacturing methods
RS20050051A (en) Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity
WO2009047006A3 (en) Amphoteric liposomes comprising neutral lipids
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
CA2156991A1 (en) Compositions which are suitable for employment as antidotes to blood anticoagulants, and their use
WO2003015715A3 (en) Tetrahydroquinoline derivatives as antithrombotic agents
WO2005020959A3 (en) Novel drug compositions and dosage forms of topiramate
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
WO2002002519A3 (en) THROMBIN OR FACTOR Xa INHIBITORS
WO2007103931A3 (en) Nanofluidized b-12 composition and process for treating pernicious anemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0051

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003770985

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11041165

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 91802003

Country of ref document: AT

WWP Wipo information: published in national office

Ref document number: 2003770985

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP